Charles M. Baum - Nov 28, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
President,Founder,Head of R&D, Director
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Nov 28, 2022
Transactions value $
-$5,719,853
Form type
4
Date filed
11/28/2022, 06:01 PM
Previous filing
Jun 16, 2022
Next filing
Dec 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Options Exercise $1.21M +69.3K +54.15% $17.41 197K Nov 28, 2022 Direct F1
transaction MRTX Common Stock Sale -$6.93M -69.3K -35.13% $100.00 128K Nov 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Employee Stock Option (Right to Buy) Options Exercise $0 -69.3K -50% $0.00 69.3K Nov 28, 2022 Common Stock 69.3K $17.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.